新型抗真菌药物研究进展

摘要/Abstract

摘要：

侵袭性真菌感染（invasive fungal infections，IFI）以其逐年上升的发病率和致死率，已经成为人类健康的严重威胁。临床常用的抗真菌药物包括氮唑类、多烯类以及棘白菌素类等。药物治疗作为应对IFI的主要策略，现有的药物种类明显不足，并且受到真菌耐药性和药物毒副作用等越来越多的制约，使得对抗真菌新药的需求愈加迫切。新型抗真菌药物的研发策略主要包括改造现有临床常用药物和发现新靶点药物两个方面。近年值得关注的研发中的新型抗真菌药物包括：氮唑类药物VT-1161和VT-1129、葡聚糖合成酶抑制剂CD101和SCY-078、GPI锚合成抑制剂E1210、嘧啶合成抑制剂F901318、抗真菌中药和增效剂，以及其他抗真菌新药如T-2307、尼可霉素Z和VL-2397等。该文主要综述了上述新药的研究进展，包括作用机制、体内外活性以及临床试验等。

关键词: 抗真菌药物, 氮唑类, 葡聚糖合成酶抑制剂, 靶点, 中药, 临床试验

中图分类号:

R978.5

刘昱, 阎澜, 姜远英. 新型抗真菌药物研究进展[J]. 中国真菌学杂志, 2018, 13(2): 105-113.

参考文献

[1] Campoy S,Adrio JL.Antifungals[J].Biochem Pharmacol,2017,133:86-96.
[2] Peyton LR,Gallagher S,Hashemzadeh M.Triazole antifungals:a review[J].Drugs Today (Barc),2015,51(12):705-718.
[3] Moore JN,Healy JR,Kraft WK.Pharmacologic and clinical evaluation of posaconazole[J].Expert Rev Clin Pharmacol,2015,83(3):321-334.
[4] Shirley M,Scott LJ.Isavuconazole:a review in invasive aspergillosis and mucormycosis[J].Drugs,2016,76(17):1647-1657.
[5] Osherov N,Kontoyiannis DP.The anti-Aspergillus drug pipeline:is the glass half full or empty?[J].Med Mycol,2017,55(1):118-124.
[6] Torrado JJ,Espada R,Ballesteros MP,et al.Amphotericin B formulations and drug targeting[J].J Pharm Sci, 2008,97(7):2405-2425.
[7] Halperin A,Shadkchan Y,Pisarevsky E,et al.Novel watersoluble amphotericin B-PEG conjugates with low toxicity and potent in vivo efficacy[J]. J Med Chem,2016,59(3):1197-1206.
[8] Ickowicz DE,Farber S,Sionov E,et al.Activity, reduced toxicity, and scale-up synthesis of amphotericin B-conjugated polysaccharide[J]. Biomacromolecules,2014,15(6):2079-2089.
[9] Shirkhani K,Teo I,Armstrong-James D,et al.Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis[J].Nanomedicine,2015,11(5):1217-1226.
[10] Denning DW.Echinocandin antifungal drugs[J].Lancet,2003,362(9390):1142-1151.
[11] Chang CC,Slavin MA,Chen SC.New developments and directions in the clinical application of the echinocandins[J].Arch Toxicol,2017,91(4):1613-1621.
[12] Roemer T,Krysan DJ.Antifungal drug development:challenges, unmet clinical needs, and new approaches[J]. Cold Spring Harb Perspect Med,2014,4(5):a019703.
[13] Denning DW,BromLey MJ.Infectious Disease. How to bolster the antifungal pipeline[J].Science,2015,347(6229):1414-1416.
[14] Hoekstra WJ,Garvey EP,Moore WR,et al.Design and optimization of highly-selective fungal CYP51 inhibitors[J].Bioorg Med Chem Lett,2014,24(15):3455-3458.
[15] Warrilow AGS,Martel CM,Parker JE,et al.The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme[J].Antimicrob Agents Chemother,2014,58(12):7121-7127.
[16] Garvey EP,Hoekstra WJ,Schotzinger RJ,et al.Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis[J].Antimicrob Agents Chemother,2015,59(9):5567-5573.
[17] Shubitz LF,Trinh HT,Galgiani JN,et al.Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models[J].Antimicrob Agents Chemother,2015,59(12):7249-7254.
[18] Shubitz LF,Roy ME,Trinh HT,et al.Efficacy of the investigational antifungal VT-1161 in treating naturally occurring Coccidioidomycosis in dogs[J].Antimicrob Agents Chemother,2017,61(5):e00111-17.
[19] Garvey EP,Hoekstra WJ,Moore WR,et al.VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model[J].Antimicrob Agents Chemother,2015,59(4):1992-1997.
[20] Gebremariam T,Wiederhold NP,Fothergill AW,et al.VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection[J].Antimicrob Agents Chemother,2015,59(12):7815-7817.
[21] Lockhart SR,Fothergill AW,Wiederhold NP,et al. The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii[J].Antimicrob Agents Chemother,2016,60(4):2528-2531.
[22] Nielsen K,Vedula P,Smith KD,et al.Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs[J].Med Mycol,2017,55(4):453-456.
[23] Warrilow AGS,Parker JE,Price CL,et al.The investigational drug VT-1129 is a highly potent inhibitor of Cryptococcus species CYP51 but only weakly inhibits the human enzyme[J].Antimicrob Agents Chemother,2016,60(8):4530-4538.
[24] Schell WA,Jones AM,Garvey EP,et al.Fungal CYP51 Inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds[J].Antimicrob Agents Chemother,2017,61(3):e01817-16.
[25] Hargrove TY,Garvey EP,Hoekstra WJ,et al. Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14α-Demethylase provides insights into its broad-spectrum antifungal activity[J].Antimicrob Agents Chemother,2017,61(7):e00570-17.
[26] Wiederhold NP,Patterson HP,Tran BH,et al. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus[J]. J Antimicrob Chemother,2018,73(2):404-408.
[27] Ong V,James KD,Smith S,et al.Pharmacokinetics of the novel echinocandin CD101 in multiple animal species[J].Antimicrob Agents Chemother,2017,61(4):e01626-16.
[28] Sandison T,Ong V,Lee J,et al.Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults[J].Antimicrob Agents Chemother,2017,61(2):e01627-16.
[29] Zhao Y, Perez WB,Jiménez-Ortigosa C,et al. CD101:a novel long-acting echinocandin[J].Cell Microbiol,2016,18(9):1308-1316.
[30] Pfaller MA,Messer SA,Rhomberg PR,et al.Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin-and azole-resistant isolates[J].J Antimicrob Chemother,2016,71(10):2868-2873.
[31] James KD,Laudeman CP,Malkar NB,et al. Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties[J].Antimicrob Agents Chemother,2017,61(2):e01541-16.
[32] Pfaller MA,Messer SA,Rhomberg PR,et al. Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 Antifungal Surveillance Program[J].Antimicrob Agents Chemother,2017,61(3):e02045-16.
[33] Pfaller MA,Messer SA,Rhomberg PR,et al.CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program[J].Int J Antimicrob Agents,2017,50(3):352-358.
[34] Ong V,Hough G,Schlosser M,et al.Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin[J].Antimicrob Agents Chemother,2016,60(11):6872-6879.
[35] Zhao Y,Prideaux B, Nagasaki Y,et al. Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model[J].Antimicrob Agents Chemother,2017,61(10):e01009-17.
[36] Krishnan BR,James KD,Polowy K,et al.CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility[J].J Antibiot (Tokyo),2017,70(2):130-135.
[37] Lakota EA,Bader JC,Ong V,et al.Pharmacological basis of CD101 efficacy:exposure shape matters[J]. Antimicrob Agents Chemother,2017,61(11):e00758-17.
[38] Hector RF,Bierer DE.New β-glucan inhibitors as antifungal drugs[J]. Expert Opin Ther Pat,2011,21(10):1597-1610.
[39] Onishi J,Meinz M,Thompson J,et al.Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors[J]. Antimicrob Agents Chemother,2000,44(2):368-377.
[40] Scorneaux B,Angulo D,Borroto-Esoda K,et al.SCY-078 is fungicidal against Candida species in time-kill studies[J].Antimicrob Agents Chemother,2017,61(3):e01961-16.
[41] Lepak AJ,Marchillo K,Andes DR.Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078(MK-3118), using an in vivo murine invasive candidiasis model[J].Antimicrob Agents Chemother,2015,59(2):1265-1272.
[42] Schell WA,Jones AM,Borroto-Esoda K,et al.Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species[J].Antimicrob Agents Chemother,2017,61(11):e01102-17.
[43] Pfaller MA,Messer SA,Motyl MR,et al.Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)[J]. J Antimicrob Chemother,2013,68(4):858-863.
[44] Pfaller MA,Messer SA,Motyl MR,et al.In vitro activitity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods[J].Antimicrob. Agents Chemother,2013,57(2):1065-1068.
[45] Jimenez-Ortigosa C,Paderu P,Motyl MR,et al.Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates[J].Antimicrob Agents Chemother,2014,58(2):1248-1251.
[46] Pfaller MA,Messer SA,Rhomberg PR,et al.Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species[J].Antimicrob Agents Chemother,2017,61(8):e00161-17.
[47] Lamoth F,Alexander BD.Antifungal activities of SCY-078(MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates[J].Antimicrob Agents Chemother,2015,59(7):4308-4311.
[48] Larkin E,Hager C,Chandra J,et al.The emerging pathogen Candida auris:growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation[J].Antimicrob Agents Chemother,2017,61(5):e02396-16.
[49] Wring SA,Randolph R,Park S,et al.Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis[J].Antimicrob Agents Chemother,2017,61(4):e02068-16.
[50] Richard ML,Plaine A.Comprehensive analysis of glycosylphosphatidylinositol-anchored proteins in Candida albicans[J].Eukaryot Cell,2007,6(2):119-133.
[51] Tsukahara K,Hata K,Nakamoto K,et al.Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly[J].Mol Microbiol,2003,48(4):1029-1042.
[52] Umemura M,Okamoto M,Nakayama K,et al.GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast[J]. J Biol Chem,2003,278(26):23639-23647.
[53] Watanabe NA,Miyazaki M,Horii T,et al.E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis[J].Antimicrob. Agents Chemother,2012,56(2):960-971.
[54] Miyazaki M,Horii T,Hata K,et al.In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds[J].Antimicrob Agents Chemother,2011,55(10):4652-4658.
[55] Pfaller MA,Hata K,Jones RN,et al.In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method[J].Diagn Microbiol Infect Dis,2011,71(2):167-170.
[56] Pfaller MA,Duncanson F,Messer SA,et al.In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods[J].Antimicrob Agents Chemother,2011,55(11):5155-5158.
[57] Castanheira M,Duncanson FP,Diekema DJ,et al.Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods[J].Antimicrob Agents Chemother,2012,56(1):352-357.
[58] Wiederhold NP,Najvar LK,Fothergill AW,et al.The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans[J].Antimicrob Agents Chemother,2015,59(1):690-692.
[59] Hata K,Horii T,Miyazaki M,et al.Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis[J].Antimicrob Agents Chemother,2011,55(10):4543-4551.
[60] Oliver JD,Sibley GE,Beckmann N,et al.F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase[J].Proc Natl Acad Sci U S A,2016,113(45):12809-12814.
[61] Buil JB,Rijs AJMM,Meis JF,et al.In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates[J].J Antimicrob Chemother,2017,72(9):2548-2552.
[62] Miao H,Jiang Y,Cao Y,et al.Inhibitory effect of Shikonin on Candida albicans growth[J].Biol Pharm Bull, 2012,35(11):1956-1963.
[63] Li DD,Zhao LX,Jiang YY,et al.In vitro and in vivo activities of pterostilbene against Candida albicans biofilms[J].Antimicrob Agents Chemother,2014,58(4):2344-2355.
[64] Hu DD,Zhang RL,Jiang YY,et al.The structure-activity relationship of pterostilbene against Candida albicans biofilms[J]. Molecules, 2017,22(3):E360.
[65] Zhao LX,Li DD,Jiang YY et al.Effect of tetrandrine against Candida albicans biofilms[J].PLoS One,2013,8(11):e79671.
[66] Quan H,Cao YY,Jiang YY,et al.Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole[J].Antimicrob Agents Chemother,2006,50(3):1096-1099.
[67] Xu Y,Wang Y,Jiang YY,et al.Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans:endogenous ROS augmentation[J]. J Proteome Res,2009,8(11):5296-5304.
[68] Li DD,Xu Y,Jiang YY,et al.Fluconazole assists berberine to kill fluconazole-resistant Candida albicans[J]. Antimicrob Agents Chemother,2013,57(12):6016-6027.
[69] Zhu SL,Yan L,Jiang YY,et al.Berberine inhibits fluphenazine-induced up-regulation of CDR1 in Candida albicans[J].Biol Pharm Bull,2014, 37(2):268-273.
[70] Huang S,Cao YY,Jiang YY,et al.In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole[J].Biol Pharm Bull,2008,31(12):2234-2236.
[71] 赵柳娅,蒋京辰,姚响文,等.黄芩素与氟康唑协同抗白念珠菌生物被膜作用研究[J].中国真菌学杂志,2014,9(2):70-74.
[72] Dai BD,Cao YY,Jiang YY,et al.Baicalein induces programmed cell death in Candida albicans[J].J Microbiol Biotechnol,2009,19(8):803-809.
[73] Liu W,Li LP,Jiang YY,et al.Synergistic antifungal effect of glabridin and fluconazole[J].PLoS One,2014,9(7):e103442.
[74] Li DD,Chai D,Jiang YY.Potent in vitro synergism of fluconazole and osthole against fluconazole-resistant Candida albicans[J].Antimicrob Agents Chemother,2017,61(8):e00436-17.
[75] Han B,Cao YB,Jiang YY,et al.Antifungal activity of Rubus chingii extract combined with fluconazole against fluconazole-resistant Candida albicans[J].Microbiol Immunol,2016,60(2):82-92.
[76] Zhang L,Lin H,Jiang YY,et al.Antifungal activity of the ethanol extract from Flos Rosae Chinensis with activity against fluconazole-resistant clinical Candida[J].Evid Based Complement Alternat Med,2017,2017:4780746.
[77] Mitsuyama J,Nomura N,Hashimoto K,et al.In vitro and in vivo antifungal activities of T-2307, a novel arylamidine[J].Antimicrob Agents Chemother,2008,52(4):1318-1324.
[78] Wiederhold NP,Najvar LK,Fothergill AW,et al.The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans[J].Antimicrob Agents Chemother,2015,59(2):1341-1343.
[79] Wiederhold NP,Najvar LK,Fothergill AW,et al.The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata[J].J Antimicrob Chemother,2016,71(3):692-695.
[80] Nishikawa H,Fukuda Y,Mitsuyama J,et al.In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii:an emerging fungal pathogen[J]. J Antimicrob Chemother,2017,72(6):1709-1713.
[81] Yamada E,Nishikawa H,Nomura N,et al.T-2307 shows efficacy in murine model of Candida glabrata infection despite in vitro trailing growth phenomena[J].Antimicrob Agents Chemother,2010,54(9):3630-3634.
[82] Shibata T,Takahashi T,Yamada E,et al.T-2307 causes collapse of mitochondrial membrane potential in yeast[J].Antimicrob Agents Chemother,2012,56(11):5892-5897.
[83] Holden WM,Fites JS,Reinert LK,et al.Nikkomycin Z is an effective inhibitor of the chytrid fungus linked to global amphibian declines[J].Fungal Biol,2014,118(1):48-60.
[84] Shubitz LF,Trinh HT,Perrill RH,et al.Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials[J].J Infect Dis,2014,209(12):1949-1954.
[85] Arendrup MC,Jensen RH,Cuenca-Estrella M.In vitro activity of ASP2397 against Aspergillus isolates with or without acquired azole resistance mechanisms[J].Antimicrob Agents Chemother,2015,60(1):532-536.
[86] Nakamura I,Kanasaki R,Yoshikawa K,et al.Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection[J].J Antibiot (Tokyo),2017,70(1):41-44.
[87] Nakamura I,Yoshimura S,Masaki T,et al.ASP2397:a novel antifungal agent produced by Acremonium persicinum MF-347833[J].J Antibiot (Tokyo),2017,70(1):45-51.